... diseases (DTC). Methods: We retrospectively evaluated 3,250 consecutive patients with thyroid nodular disease who underwent fine-needle aspiration cytology with adequate sample. After exclusion of medullary thyroid cancer (MTC) patients were divided according to the presence/absence of thyroid autoimmunity...

...). The keywords used for the disease “(medullary thyroid cancer OR medullary thyroid carcinoma)” were entered as free-text terms, in an attempt to maximize the sensitivity of the search strategy and indeed they rendered the largest amount of results. A computerized literature search in MEDLINE, EMBASE...

...Laura Moss; Catrin Cox; Jonathan Wadsley; Kate Newbold; Mark W.J. Strachan; Maralyn Druce; Neil Tolley; Kathryn Graham; Sarah Jefferies; Lydia Fresco; Suganya Sivabalasingham; Alistair Balfour; Chris Hurt Background: Medullary thyroid cancer (MTC) is a neuroendocrine tumour and a rare variant...

.... The right upper part of the figure also shows a focal uptake coinciding with the mammary node. Medullary thyroid cancer Calcitonin Carcinoembryonic antigen The most important clinical prognostic factors for medullary thyroid carcinoma are basal serum calcitonin (Ctn) at diagnosis...

...Luisa Paschke; Thomas Lincke; Katja Sibylle Mühlberg; Wolfram J. Jabs; Tom H. Lindner; Ralf Paschke Cabozantinib and lenvatinib have been approved for the treatment of progressive medullary thyroid cancer and radioiodine-resistant thyroid cancer, respectively. Both phase III trials of cabozantinib...

.... Precision medicine Differentiated thyroid cancer Medullary thyroid cancer Thyroid cancer Thyroid nodule Molecular Tests The advances in understanding the molecular pathways in tumorigenesis have identified many of the genetic abnormalities involved in thyroid cell transformation [ 10,11...

...Stacey A. Fedewa; Ahmedin Jemal; Amy Y. Chen Background/Aim: Beginning in 2011, the Food and Drug Administration (FDA) approved the use of multikinase inhibitors (MKIs) for medullary thyroid cancers (MTCs), and in 2013 MKIs were approved for metastatic differentiated thyroid cancers (DTCs). However...

... more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher. Study Design: In this open-label, multicentre, phase III study, patients with locally advanced or metastatic medullary thyroid cancer were randomized to a patient outreach programme (outreach) or a standard...

...Laura Fugazzola Medullary thyroid cancer can be highly aggressive, especially if the diagnosis is done in advanced stages. Early diagnosis is based on RET genetic testing, for familial forms, and on the routine measurement of calcitonin (Ct). Nevertheless, since false-positive results can...

...R. Elisei; M. Alevizaki; B. Conte-Devolx; K. Frank-Raue; V. Leite; G.R. Williams Twenty-five percent of medullary thyroid cancers (MTC) are familial and inherited as an autosomal dominant trait. Three different phenotypes can be distinguished: multiple endocrine neoplasia (MEN) types 2A and 2B...

...M. Schlumberger; L. Bastholt; H. Dralle; B. Jarzab; F. Pacini; J.W.A. Smit; The European Thyroid Association Task Force Distant metastases are the main cause of death in patients with medullary thyroid cancer (MTC). These 21 recommendations focus on MTC patients with distant metastases...